Lyell Immunopharma Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 251
- Market Cap
- $373.7M
- Website
- http://www.lyell.com
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
- Conditions
- Lupus NephritisSystemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06153095
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) Medical Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
A Biomarker Screening Protocol for Participants With Solid Tumors
- Conditions
- Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Advanced Breast CancerAdvanced Lung CarcinomaNSCLCNSCLC, RecurrentNSCLC Stage IV
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05891197
- Locations
- 🇺🇸
Accellacare, Rocky Mount, North Carolina, United States
Study of LYL314 in Aggressive Large B-Cell Lymphoma
- Conditions
- Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin LymphomaLarge B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05826535
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸University of California-Irvine Medical Center, Irvine, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Investigate LYL845 in Adults With Solid Tumors
- Conditions
- MelanomaNon-small Cell Lung CancerColorectal Cancer
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05573035
- Locations
- 🇺🇸
UC Davis Coomprehensive Cancer Center, Sacramento, California, United States
🇺🇸UCLA Medical Center, Santa Monica, California, United States
🇺🇸Stanford University, Stanford, California, United States
A Study to Investigate LYL797 in Adults With Solid Tumors
- Conditions
- Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4Advanced Breast CancerAdvanced Lung CarcinomaNSCLCNSCLC, Recurrent
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Lyell Immunopharma, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT05274451
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California, Los Angeles, Santa Monica, California, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
News
Lyell's IMPT-314 CAR T-cell Therapy Shows Promise in B-Cell Lymphoma Trial
Lyell's IMPT-314 demonstrated a 94% objective response rate and a 71% complete response rate in CAR T-naive patients with large B-cell lymphoma.